We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
FFIE | Faraday Future Intelligent Electric Inc | 0.7899 | 0.09 | 12.86% | 4,858,344 |
SYRA | Syra Health Corporation | 1.8804 | 0.1804 | 10.61% | 11,895 |
FLJ | FLJ Group Limited | 0.49 | 0.037 | 8.17% | 6,512 |
SNCR | Synchronoss Technologies Inc | 10.81 | 0.81 | 8.10% | 2,500 |
SNGX | Soligenix Inc | 0.3868 | 0.0233 | 6.41% | 258 |
TIRX | Tian Ruixiang Holdings Ltd | 3.6898 | 0.2098 | 6.03% | 475 |
EKSO | Ekso Bionics Holdings Inc | 1.4387 | 0.0787 | 5.79% | 501 |
CSCO | Cisco Systems Inc | 52.44 | 2.75 | 5.53% | 325,529 |
SFIX | Stitch Fix Inc | 2.60 | 0.135 | 5.48% | 2,496 |
NN | NextNav Inc | 7.85 | 0.40 | 5.37% | 5,379 |
SINT | SiNtx Technologies Inc | 0.134 | 0.0068 | 5.35% | 3,692,762 |
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.
AEye, Inc. (Nasdaq: LIDR), a global leader in adaptive, high performance lidar solutions, today announced its results for the first quarter ended March 31, 2024.
SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share (or pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of ...
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 65,935.88 | 4,389.03 | 7.13% | 1.29T | 4,834,958,619 |
ETH | Ethereum | 3,016.47 | 135.89 | 4.72% | 362.84B | 1,894,792,677 |
USDT | Tether USD | 1.00 | 0.00048 | 0.05% | 97.84B | 244,888,546 |
BNB | Binance Coin | 586.59 | 19.80 | 3.49% | 92.56B | 307,580,094 |
SOL | Solana | 154.86 | 12.85 | 9.05% | 68.22B | 1,114,491,029 |
STETH | stETH | 3,013.09 | 146.22 | 5.10% | 29.51B | 4,931,524 |
XRP | Ripple | 0.5182 | 0.0183 | 3.66% | 28.33B | 280,910,508 |
USDC | USD Coin | 0.99999 | -0.00001 | 0.00% | 28.07B | 994,856,772 |
TONCOIN | Wrapped TON Coin | 7.11 | 0.258736 | 3.77% | 24.31B | 188,358,185 |
DOGE | Dogecoin | 0.1542 | 0.00879 | 6.04% | 22.1B | 485,256,505 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions